90 related articles for article (PubMed ID: 9337355)
1. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Sridhara R
J Natl Cancer Inst; 1997 Oct; 89(20):1546-7. PubMed ID: 9337355
[No Abstract] [Full Text] [Related]
2. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Minami H; Ando Y; Saka H; Shimokata K
J Natl Cancer Inst; 1997 Jul; 89(13):968-70. PubMed ID: 9214677
[No Abstract] [Full Text] [Related]
3. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin dosing in children: calculation by different formulae.
Würthwein G; Krefeld B; Gerss J; Boos J
Onkologie; 2011; 34(1-2):16-22. PubMed ID: 21346380
[TBL] [Abstract][Full Text] [Related]
5. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.
Bénézet S; Guimbaud R; Chatelut E; Chevreau C; Bugat R; Canal P
Ann Oncol; 1997 Jun; 8(6):607-9. PubMed ID: 9261532
[TBL] [Abstract][Full Text] [Related]
6. Prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Chatelut E; Canal P; Brunner V; Chevreau C; Pujol A; Boneu A; Roché H; Houin G; Bugat R
J Natl Cancer Inst; 1995 Apr; 87(8):573-80. PubMed ID: 7752255
[TBL] [Abstract][Full Text] [Related]
7. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
[TBL] [Abstract][Full Text] [Related]
8. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
Br J Cancer; 1997; 76(8):1067-71. PubMed ID: 9376268
[TBL] [Abstract][Full Text] [Related]
9. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Fujiwara Y; Takahashi T; Yamakido M; Ohune T; Tsuya T; Egorin MJ
J Natl Cancer Inst; 1997 Feb; 89(3):260-2. PubMed ID: 9017009
[No Abstract] [Full Text] [Related]
10. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin.
Thomas F; Séronie-Vivien S; Gladieff L; Dalenc F; Durrand V; Malard L; Lafont T; Poublanc M; Bugat R; Chatelut E
Clin Pharmacokinet; 2005; 44(12):1305-16. PubMed ID: 16372828
[TBL] [Abstract][Full Text] [Related]
11. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
[TBL] [Abstract][Full Text] [Related]
12. [Prediction of carboplatin clearance from morphological and biological patient characteristics].
Chatelut E; Dezeuze A; Lavit M; Chevreau C; Pujol A; Boneu A; Roché H; Houin G; Bugat R; Canal P
Bull Cancer; 1995 Nov; 82(11):946-53. PubMed ID: 8535021
[TBL] [Abstract][Full Text] [Related]
13. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
15. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
16. Difficulties in carboplatin dosage due to different methods of serum creatinine determination.
Groth G; Gatzemeier U
Lung Cancer; 2002 Oct; 38(1):97-8. PubMed ID: 12367800
[No Abstract] [Full Text] [Related]
17. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of two dose individualisation methods for carboplatin.
Desoize B; Dufour R; Urien S; Kaltenbach M; Colin P
Anticancer Res; 1996; 16(4A):2073-8. PubMed ID: 8712745
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
20. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]